雌激素受体、孕激素受体、C-erbB-2和Ki-67在子宫内膜癌中的表达及其与临床病理相关性

目的 探讨雌激素受体（ER）、孕激素受体（PR）、C-erbB-2和Ki-67在不同子宫内膜组织中的表达及其与临床病理的相关性。方法 采用免疫组化S-P法检测2004年1月至2013年1月郑州人民医院病理科存档30例正常子宫内膜、30例不典型增生、80例子宫内膜癌组织中ER、PR、C-erbB-2、Ki-67的表达。结果　ER、PR在正常子宫内膜、不典型增生和子宫内膜癌中表达逐渐降低(P<0.05)，在不同分化子宫内膜癌组织类型中表达有差异(P<0.05)；C-erbB-2在正常子宫内膜中不表达，在不典型增生中表达为53.33%和子宫内膜癌中表达为80.00%，两两比较差异有统计学意义(P<0.05)；Ki-67在正常子宫内膜仅有少量表达，在不典型增生子宫内膜中表达为33.33%和子宫内膜癌中表达为63.75%，差异均有统计学意义(P<0.05)。C-erbB-2及Ki-67的表达与子宫内膜癌的分化程度、临床分期、肌层浸润深度及淋巴结转移4种病理特征均有关(P<0.05)。结论　ER、PR、C-erbB-2和Ki-67表达与子宫内膜癌的临床病理相关，可作为判断子宫内膜癌预后及指导临床治疗的指标。

Correlation between expression of ER,PR,C-erbB-2 and Ki-67 and its clinical pathology in endometrial carcinoma.

Abstract： Objective To investigate the expression of ER、PR、C-erbB-2 and Ki-67 in endometrial carcinoma and the correlation between their expression and clinical pathology. Methods Expression of ER,PR,C-erbB-2 and Ki-67 were detected in 30 normal endometrium,30 atypical hyperplasia and 80 endometrial carcinoma, using immunohistochemical S-P assay.Results The expression of ER,PR are gradually reduced in normal endometrium, atypical hyperplasia and endometrial carcinoma(P<0.05)，The expression were difference in different differentiation endometrial carcinoma tissue types(P<0.05);C-erbB-2 was rarely expressed in normal endometrium while its expression rate in atypical hyperplasia was 53.33%，and endometrial carcinoma was 80.00%, which had statistical significance(P<0.05);The expression of Ki-67 in atypical hyperplasia was 33.33%,and endometrial carcinoma was 63.75%, showing significant difference(P<0.05). The expression of C-erbB-2 and Ki-67 was related to differentiated degree, clinical stage, muscle invasion and lymphatic metastasis(P<0.05). Conclusion The expression of ER,PR,C-erbB-2 and Ki-67 were related to clinical pathology of endometrial carcinoma，which can be used as indicators to judge the endometrial cancer prognosis and clinical treatment.